Idexx Laboratories Inc (IDXX)

In Vitro & In Vivo Diagnostic Substances

Latest Price

$522.19

TTM P/E

36.70

Normalized P/E

48.20

Div Yield

Book Value

20.44

P/B Ratio

25.54

Valuation metrics

EPS: $13.08

Book value / share: $20.14

Formula: √(22.5 × EPS × BVPS)

Graham Number

$76.99

85% downside

Norm. op. income: $932M (median of 7yr)

Tax rate: 20%

Discount rate: 10%

Growth assumption: zero (EPV is a no-growth value)

Earnings Power Value

$90.16

83% downside

Base FCF: $773M (median of recent 5yr)

Growth: 21%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$547.31

+5% upside

EPS: $13.08

Target P/E: 48×

Formula: EPS × P/E

P/E Fair Value

$627.84

+20% upside

92.8% held by institutions

Institution	Shares	Value	Ownership %	Change	Filing Date
BlackRock, Inc.	8.17M	$4.30B	10.36%	-195.4K	2026-06-30
Vanguard Capital Management LLC	5.15M	$2.71B	6.53%	-30.3K	2026-06-30
Vanguard Portfolio Management LLC	3.90M	$2.05B	4.94%	-14.3K	2026-06-30
State Street Corp	3.75M	$1.97B	4.75%	+74.5K	2026-06-30
Invesco Ltd.	3.61M	$1.90B	4.58%	+1.93M	2026-06-30
Geode Capital Management, LLC	2.56M	$1.34B	3.25%	-98.1K	2026-06-30
Bamco Inc	1.98M	$1.04B	2.51%	+343.4K	2026-06-30
Morgan Stanley	1.36M	$713.0M	1.72%	+40.1K	2026-06-30
Bank of New York Mellon Corp	1.19M	$628.0M	1.51%	-311.2K	2026-06-30
Arrowstreet Capital, Limited Partnership	1.07M	$561.0M	1.35%	+228.2K	2026-06-30